Candel Therapeutics Inc (CADL) concluded trading on Thursday at a closing price of $12.21, with 5.06 million shares of worth about $61.76 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 132.57% during that period and on February 20, 2025 the price saw a gain of about 16.62%. Currently the company’s common shares owned by public are about 32.13M shares, out of which, 30.51M shares are available for trading.
Stock saw a price change of 42.81% in past 5 days and over the past one month there was a price change of 84.86%. Year-to-date (YTD), CADL shares are showing a performance of 40.67% which increased to 609.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.34 but also hit the highest price of $14.60 during that period. The average intraday trading volume for Candel Therapeutics Inc shares is 4.06 million. The stock is currently trading 49.97% above its 20-day simple moving average (SMA20), while that difference is up 54.32% for SMA50 and it goes to 77.19% higher than SMA200.
Candel Therapeutics Inc (NASDAQ: CADL) currently have 32.13M outstanding shares and institutions hold larger chunk of about 36.03% of that.
The stock has a current market capitalization of $543.05M and its 3Y-monthly beta is at -1.21. It has posted earnings per share of -$1.74 in the same period. It has Quick Ratio of 1.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CADL, volatility over the week remained 11.35% while standing at 8.00% over the month.
Stock’s fiscal year EPS is expected to drop by -4.53% while it is estimated to increase by 25.55% in next year. EPS is likely to grow at an annualized rate of 0.88% for next 5-years, compared to annual growth of -46.75% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on Feb-21-25 offering a Buy rating for the stock and assigned a target price of $25 to it. Coverage by Canaccord Genuity stated Candel Therapeutics Inc (CADL) stock as a Buy in their note to investors on February 19, 2025, suggesting a price target of $20 for the stock. On February 07, 2025, BofA Securities Initiated their recommendations, while on December 02, 2022, H.C. Wainwright Initiated their ratings for the stock with a price target of $11. Stock get an Outperform rating from BMO Capital Markets on November 19, 2021.
